Suppr超能文献

白细胞介素10和Fcγ受体缺陷型小鼠可消除墨西哥利什曼原虫感染造成的损伤。

Interleukin 10- and Fcgamma receptor-deficient mice resolve Leishmania mexicana lesions.

作者信息

Buxbaum Laurence U, Scott Phillip

机构信息

Department of Pathobiology, University of Pennsylvania School of Veterinary Medicine, 216 ROS, 3800 Spruce Street, Philadelphia, PA 19104, USA.

出版信息

Infect Immun. 2005 Apr;73(4):2101-8. doi: 10.1128/IAI.73.4.2101-2108.2005.

Abstract

Infection of C57BL/6 (B6) mice with Leishmania mexicana is associated with a minimal immune response and chronic disease. Here we show that B6 interleukin 10-/- (IL-10-/-) mice resolve their lesions and exhibit increased gamma interferon (IFN-gamma), nitric oxide production, and delayed-type hypersensitivity. This enhanced resistance was dependent upon IL-12p40, since treatment of L. mexicana-infected IL-10-/- mice with anti-IL-12p40 monoclonal antibody abrogated healing. Antibody-opsonized L. mexicana induced IL-10 production by B6 macrophages in vitro, implicating antibody binding to Fc receptors as a mechanism involved in IL-10 production in this infection. Furthermore, B6 FcRgamma-/- mice resolve L. mexicana lesions, and lymph node cells from these mice produced less IL-10 and more IFN-gamma than cells from infected wild-type mice. These data demonstrate that removal of IL-10 or FcgammaR leads to resolution of L. mexicana disease and support a model in which ligation of FcgammaR by L. mexicana-bound immunoglobulin G promotes IL-10 production, leading to chronic disease.

摘要

用墨西哥利什曼原虫感染C57BL/6(B6)小鼠会引发轻微的免疫反应并导致慢性病。在此我们发现,B6白细胞介素10基因敲除(IL-10-/-)小鼠的损伤得以痊愈,且γ干扰素(IFN-γ)、一氧化氮的产生增加,迟发型超敏反应增强。这种增强的抵抗力依赖于IL-12p40,因为用抗IL-12p40单克隆抗体处理感染墨西哥利什曼原虫的IL-10-/-小鼠会消除其损伤愈合。抗体调理的墨西哥利什曼原虫在体外诱导B6巨噬细胞产生IL-10,这表明抗体与Fc受体的结合是该感染中IL-10产生所涉及的一种机制。此外,B6 FcRγ-/-小鼠的墨西哥利什曼原虫损伤得以痊愈,并且与感染的野生型小鼠的细胞相比,这些小鼠的淋巴结细胞产生的IL-10更少,IFN-γ更多。这些数据表明,去除IL-10或FcγR会导致墨西哥利什曼原虫病的痊愈,并支持一种模型,即与墨西哥利什曼原虫结合的免疫球蛋白G对FcγR的连接促进IL-10的产生而导致慢性病。

相似文献

1
Interleukin 10- and Fcgamma receptor-deficient mice resolve Leishmania mexicana lesions.
Infect Immun. 2005 Apr;73(4):2101-8. doi: 10.1128/IAI.73.4.2101-2108.2005.
3
FcgammaRIII mediates immunoglobulin G-induced interleukin-10 and is required for chronic Leishmania mexicana lesions.
Infect Immun. 2008 Feb;76(2):623-31. doi: 10.1128/IAI.00316-07. Epub 2007 Dec 10.
4
Vaccine-induced protection against Leishmania amazonensis is obtained in the absence of IL-12/23p40.
Immunol Lett. 2006 May 15;105(1):38-47. doi: 10.1016/j.imlet.2005.12.002. Epub 2006 Jan 13.
5
Control of New World cutaneous leishmaniasis is IL-12 independent but STAT4 dependent.
Eur J Immunol. 2002 Nov;32(11):3206-15. doi: 10.1002/1521-4141(200211)32:11<3206::AID-IMMU3206>3.0.CO;2-J.
6
Type I IFNs promote the early IFN-gamma response and the IL-10 response in Leishmania mexicana infection.
Parasite Immunol. 2010 Feb;32(2):153-60. doi: 10.1111/j.1365-3024.2009.01167.x.
8
Cysteine protease B of Leishmania mexicana inhibits host Th1 responses and protective immunity.
J Immunol. 2003 Oct 1;171(7):3711-7. doi: 10.4049/jimmunol.171.7.3711.
10
Leishmania mexicana infection induces IgG to parasite surface glycoinositol phospholipids that can induce IL-10 in mice and humans.
PLoS Negl Trop Dis. 2013 May 9;7(5):e2224. doi: 10.1371/journal.pntd.0002224. Print 2013.

引用本文的文献

1
IL-12 mRNA-LNP promotes dermal resident memory CD4 T cell development.
NPJ Vaccines. 2025 Jul 16;10(1):154. doi: 10.1038/s41541-025-01213-x.
2
MAPK/ERK activation in macrophages promotes Leishmania internalization and pathogenesis.
Microbes Infect. 2024 Jul-Aug;26(5-6):105353. doi: 10.1016/j.micinf.2024.105353. Epub 2024 May 17.
3
promotes pain-reducing metabolomic reprogramming in cutaneous lesions.
iScience. 2023 Nov 22;26(12):108502. doi: 10.1016/j.isci.2023.108502. eCollection 2023 Dec 15.
4
The cytokine/chemokine response in /HIV infection and co-infection.
Heliyon. 2023 Apr 1;9(4):e15055. doi: 10.1016/j.heliyon.2023.e15055. eCollection 2023 Apr.
5
Humoral response in Leishmaniasis.
Front Cell Infect Microbiol. 2022 Dec 12;12:1063291. doi: 10.3389/fcimb.2022.1063291. eCollection 2022.
6
Centrin-deficient Leishmania mexicana confers protection against New World cutaneous leishmaniasis.
NPJ Vaccines. 2022 Mar 2;7(1):32. doi: 10.1038/s41541-022-00449-1.
7
Potential biomarkers of immune protection in human leishmaniasis.
Med Microbiol Immunol. 2021 Jun;210(2-3):81-100. doi: 10.1007/s00430-021-00703-8. Epub 2021 May 2.
8
Role of Cytokines in Experimental and Human Visceral Leishmaniasis.
Front Cell Infect Microbiol. 2021 Feb 18;11:624009. doi: 10.3389/fcimb.2021.624009. eCollection 2021.
9
Humoral immunity in leishmaniasis - Prevention or promotion of parasite growth?
Cytokine X. 2020 Oct 31;2(4):100046. doi: 10.1016/j.cytox.2020.100046. eCollection 2020 Dec.

本文引用的文献

2
Cysteine protease B of Leishmania mexicana inhibits host Th1 responses and protective immunity.
J Immunol. 2003 Oct 1;171(7):3711-7. doi: 10.4049/jimmunol.171.7.3711.
5
The relative contribution of IL-4 receptor signaling and IL-10 to susceptibility to Leishmania major.
J Immunol. 2003 May 15;170(10):5152-8. doi: 10.4049/jimmunol.170.10.5152.
6
Control of New World cutaneous leishmaniasis is IL-12 independent but STAT4 dependent.
Eur J Immunol. 2002 Nov;32(11):3206-15. doi: 10.1002/1521-4141(200211)32:11<3206::AID-IMMU3206>3.0.CO;2-J.
7
CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity.
Nature. 2002 Dec 5;420(6915):502-7. doi: 10.1038/nature01152.
8
Leishmania pifanoi pathogenesis: selective lack of a local cutaneous response in the absence of circulating antibody.
Infect Immun. 2002 Dec;70(12):6597-605. doi: 10.1128/IAI.70.12.6597-6605.2002.
9
The immunology of susceptibility and resistance to Leishmania major in mice.
Nat Rev Immunol. 2002 Nov;2(11):845-58. doi: 10.1038/nri933.
10
An essential role for IL-13 in maintaining a non-healing response following Leishmania mexicana infection.
Eur J Immunol. 2002 Oct;32(10):2923-33. doi: 10.1002/1521-4141(2002010)32:10<2923::AID-IMMU2923>3.0.CO;2-E.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验